NCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
Clinical Trials
8 trialsNCT07416058 2026-02-17
PHOENIX
Guangdong Association of Clinical Trials
Phase 2 Not yet recruiting
NCT07376499 2026-01-29
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 2 Not yet recruiting
NCT07097948 2025-08-01
Adjuvant
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT06963502 2025-05-09
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT06951841 2025-04-30
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 4 Not yet recruiting
NCT06648200 2024-10-18
Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT06142617 2023-11-21
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
Peking Union Medical College Hospital
Phase 2 Not yet recruiting